MoonLake Immunotherapeutics MLTX Operating Cash Flow
Operating Cash Flow at other companies
Other financials
Where this comes from
Reported directly by MoonLake Immunotherapeutics in its filing.
Tagged under the XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities.
The official record: MoonLake Immunotherapeutics’s 10-Q, filed May 11, 2026, on SEC EDGAR. View the filing →
Ask your AI about MoonLake Immunotherapeutics's operating cash flow.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is MoonLake Immunotherapeutics's operating cash flow?
- MoonLake Immunotherapeutics (MLTX) reported operating cash flow of -$66.29M in Q1 2026.
- How has MoonLake Immunotherapeutics's operating cash flow changed year-over-year?
- MoonLake Immunotherapeutics's operating cash flow decreased by 73.8% year-over-year, from -$38.14M to -$66.29M.
- What is the long-term trend for MoonLake Immunotherapeutics's operating cash flow?
- Over 4 years (2021 to 2025), MoonLake Immunotherapeutics's operating cash flow has grown at a 32.9% compound annual growth rate (CAGR), from -$62.9M to -$196.01M.
- What does operating cash flow mean?
- Total cash generated by or used in core business operations — the single most important cash flow metric for assessing business health.